Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02163317 · ClinicalTrials.gov registry record · NA

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

A NA study, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
12
Enrollment target

NCT02163317 is a NA study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02163317, a NA study, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

This pilot clinical trial studies magnetic resonance (MRI)-guided focal stereotactic radiosurgery (SRS) in treating patients with low- or intermediate-risk localized prostate cancer. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Interventions

  • OTHER quality-of-life assessment
  • RADIATION stereotactic radiosurgery
  • DEVICE magnetic resonance imaging
  • PROCEDURE Serum Prostate Antigen Test
  • PROCEDURE Digital Rectal Exam

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2016-02-16
Est. Completion 2021-07-28
Phase NA

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT02163317

The ClinicalTrials.gov registry entry for NCT02163317 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which quality-of-life assessment is the first listed.

NCT02163317 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02163317 about?

NCT02163317 is a clinical study titled "Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer". This pilot clinical trial studies magnetic resonance (MRI)-guided focal stereotactic radiosurgery (SRS) in treating patients with low- or intermediate-risk localized prostate cancer. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

What is the current status of trial NCT02163317?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2016-02-16. Estimated completion is 2021-07-28.

What interventions are being tested in trial NCT02163317?

The interventions under investigation include: quality-of-life assessment (OTHER), stereotactic radiosurgery (RADIATION), magnetic resonance imaging (DEVICE), Serum Prostate Antigen Test (PROCEDURE), Digital Rectal Exam (PROCEDURE).

Who is sponsoring clinical trial NCT02163317?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.